Ovarian Cancer

Part 1 Genetic aspects; risk of ovarian cancer associated with a family history - preliminary report of the OPCS study, Bruce Ponder; hereditary ovarian cancer, Henry T. Lynch; genetic perspective in ovarian cancer, Stig Kullander; discussion, Bruce Ponder. Part 2 Biological aspects: ovarian cancer biology - progress and problems, Sir Walter Bodmer; animal models of ovarian cancer, Frances Balkwill; discussion; new approaches in breast cancer research, Ruth Sager; discussion; regulatory mechanisms in ascitic fluid, Gordon Mills; the role of oncogenes in ovarian cancer, William Guillick; the prognostic value of steroid receptors, growth factors and growth receptor factors in ovarian cancer, Robin Leake; discussion. Part 3 Biological aspects: immunological control of ovarian cancer, Jonathan Berek; discussion; MHC expressions on tumour cells, Hilliard Festenstein; discussion; agNOR counts in borderline ovarian tumours, Wayne Kinsey; discussion; flow cytometric quantitation of p62 and DNA in serious papillary ovarian cancer, James Watson; drug resistance analysis in populations of individual cells using flow cytometry, James Watson; ras oncogene expression in advanced ovarian cancer; discussion; the pathology of early malignant change, Harold Fox; intraperitoneal and retroperitoneal spread of ovarian cancer, Helmut Pickel; discussion. Part 4 Early detection and screening: does ovarian adenocarcinoma arise from pre-existing benign cysts?; the case against, Harold Fox; malignant potential of benign ovarian cysts; the case for, Malcolm Anderson; Malcolm Anderson; discussion; potential screening tests for ovarian cancer, Ian Jacobs; discussion; tumour markers and the adnexal mass, Bill Creasman; discussion; developments in ultrasound screening for early ovarian cancer, Stuart Campbell; the evaluation of screening tests for ovarian cancer, Howard Cuckle; population-based studies of ovarian cancer screening - one way ahead?, Frank Sharp; discussion; the value of a combination of tumour markers in ovarian cancer, Manfred Lahousen; potential future screening markers, Robert Bast; discussion. Part 5 Update on potential advances in therapy: dose intensity considerations in chemotherapy, Leslie Levin; single versus multiple agent regimes, Bill Creasman; the place for single agent chemotherapy, Stan Kaye; discussion; high-dose chemotherapy and autologous bone marrow transplantation in epithelial ovarian cancer, Frank G. Lawton; care of the patient with ovarian cancer - a quality of life perspective, Denny DePetrillo; intraperitoneal therapy in ovarian cancer, George Blackledge; (Partial contents)